Why the study?
Does continuous intravenous epoprostenol improve symptoms, hemodynamics, and survival in patients with severe primary pulmonary hypertension?
Does continuous intravenous epoprostenol improve symptoms, hemodynamics, and survival in patients with severe primary pulmonary hypertension?
Continuous intravenous epoprostenol improves survival, symptoms, and hemodynamics in patients with severe primary pulmonary hypertension compared to conventional therapy.
May support epoprostenol in severe primary pulmonary hypertension; leaves open need for randomized confirmation.
As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Barst et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: